SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)

C Iking-Konert,H Schulze-Koops,G Gauler,A Engel,G.-R Burmester,A Rubbert-Roth,M.A Peters,T Dörner,H.-P Tony,R Schwenke

doi:10.1136/annrheumdis-2015-eular.4500

SAT0183 Patient Reported Outcomes (PRO) of the Mirai: Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed by Rituximab in DMARD-IR Patients with Rheumatoid Arthritis (MIRAI)

C Iking-Konert, H Schulze-Koops + Show 8 more

https://doi.org/10.1136/annrheumdis-2015-eular.4500

Copy DOI

Journal: Annals of the Rheumatic Diseases

Publication Date: Jun 1, 2015

Affiliation: Eppendorf (Germany), University Clinic of Traumatology, Center for Rheumatology, Charité - Universitätsmedizin Berlin

#Partial Responders #Tocilizumab + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

BackgroundMIRAI (NCT01332994) investigated the early response to the IL-6 inhibitor tocilizumab (TCZ) within a homogeneous population of biological naïve patients (pts) with moderate/severe active RA who inadequately responded to traditional...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.